GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery
Phase 2
Completed
- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- Biological: GSK 249553 vaccineBiological: Placebo
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 182
- Registration Number
- NCT00290355
- Locations
GSK Investigational Site
Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants
Phase 3
Completed
- Conditions
- TetanusHepatitis BHaemophilus Influenzae Type bDiphtheriaWhole Cell Pertussis
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 996
- Registration Number
- NCT00290303
- Locations
- 🇵🇭
GSK Investigational Site, Sampaloc, Manila, Philippines
Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants
Phase 3
Completed
- Conditions
- Acellular PertussisDiphtheriaTetanus
- Interventions
- Biological: DTPa-IPVBiological: DTPaBiological: IMOVAX Polio®
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2018-10-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 458
- Registration Number
- NCT00290342
- Locations
- 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of
Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 Years
Phase 3
Completed
- Conditions
- Infections, Papillomavirus
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 300
- Registration Number
- NCT00290277
- Locations
- 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of
Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,6 Month Schedule
Phase 3
Completed
- Conditions
- Hepatitis AHepatitis B
- Interventions
- Biological: TWINRIX™ ADULTBiological: Engerix TM
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 178
- Registration Number
- NCT00289744
- Locations
- 🇧🇪
GSK Investigational Site, Wilrijk, Belgium
Long-term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Mth Schedule in Healthy Adults
Phase 3
Completed
- Conditions
- Hepatitis BHepatitis A
- Interventions
- Biological: Twinrix™
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 50
- Registration Number
- NCT00289770
- Locations
- 🇧🇪
GSK Investigational Site, Wilrijk, Belgium
Assess Feasibility of an Acellular Pertussis Vaccine (Pa) Given Soon After Birth, Followed by 3-dose Primary Vaccination With the DTPa-HBV-IPV/Hib Vaccine
Phase 2
Completed
- Conditions
- Hepatitis B
- Interventions
- Biological: DTPa-HBV-IPV/Hib
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 121
- Registration Number
- NCT00289796
- Locations
- 🇩🇪
GSK Investigational Site, Mainz, Rheinland-Pfalz, Germany
Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc
Phase 4
Completed
- Conditions
- Hepatitis AHepatitis B
- Interventions
- Biological: TWINRIX™Biological: HB VAX PRO™Biological: Engerix™-BBiological: HAVRIX™Biological: Vaqta™
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 596
- Registration Number
- NCT00289731
- Locations
- 🇩🇪
GSK Investigational Site, Elmshorn, Schleswig-Holstein, Germany
Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine, Injected According to 0, 6-month Schedule
Phase 4
Completed
- Conditions
- Hepatitis A
- Interventions
- Biological: Havrix™
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 78
- Registration Number
- NCT00289757
- Locations
- 🇧🇪
GSK Investigational Site, Wilrijk, Belgium
Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Month Schedule
Phase 3
Completed
- Conditions
- Hepatitis BHepatitis A
- Interventions
- Biological: Twinrix™ adult
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2018-02-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 51
- Registration Number
- NCT00289718
- Locations
- 🇧🇪
GSK Investigational Site, Gent, Belgium
© Copyright 2025. All Rights Reserved by MedPath